4,5-diazafenylfluorene-rhodanine conjugates promote anoikis in A375 cells via inhibiting PPAR-γ expression

Qiang Yin,Annoor Awadasseid,Yongnan Zhou,Ming Wang,Xuqiong Xiong,Yanling Wu,Wen Zhang
DOI: https://doi.org/10.1007/s00044-022-02928-5
2022-07-15
Medicinal Chemistry Research
Abstract:Regulation of PPAR-γ protein activity has anti-tumor effects, both activation, and inhibition. Based on the PPAR-γ protein and previous work in our laboratory, we designed and synthesized a series of 4,5-diazafenylfluorene-rhodanine conjugates and explored their anti-tumor activity and mechanism in vitro. This series of 4,5-diazafenylfluorene-rhodanine conjugates could induce rapid ubiquitin degradation of PPAR-γ to inhibit its function. And the cytotoxicity in vitro showed that these compounds had selective cytotoxicity to several kinds of tumor cells. Among them, the compound YINQ-9 possessed the best activity against melanoma A375 cells, with an IC 50 value of 4.11 μM. Further experiments demonstrated that YINQ-9 could affect the A375 cell's adhesion to the extracellular matrix and induce anoikis by inhibiting the MAPK/ERK pathway and activating the mitochondrial endogenous apoptosis pathway. This series of novel 4,5-diazafenylfluorene-rhodanine conjugates could inhibit the function of PPAR-γ by inducing ubiquitin degradation, thus inducing A375 cells to anoikis. This study provides a new direction for the design of anti-tumor drugs targeting PPAR-γ.
chemistry, medicinal
What problem does this paper attempt to address?